ClinConnect ClinConnect Logo
Search / Trial NCT06970860

Detection of Bleeding Disorders Diagnosed After Vaginal Delivery Complicated by Severe Postpartum Hemorrhage

Launched by UNIVERSITY HOSPITAL, BREST · May 6, 2025

Trial Information

Current as of July 28, 2025

Not yet recruiting

Keywords

Postpartum Hemorrhage Bleeding Disorders

ClinConnect Summary

This clinical trial is looking to understand bleeding disorders in women who had severe postpartum hemorrhage, which means they lost a lot of blood (more than 1,000 mL) after giving birth vaginally. If you’re a woman aged 18 or older who experienced this type of bleeding within the last year in a maternity unit in Finistère, you may qualify to participate in the study. However, if you are currently pregnant, have a known bleeding disorder, or take certain medications that affect blood clotting, you wouldn’t be able to join.

Participants in this study will help researchers identify any bleeding disorders that may not have been diagnosed after experiencing severe postpartum hemorrhage. While the study is not yet recruiting participants, those who qualify can expect to contribute to important research that may improve care for future mothers facing similar challenges. It's also important to know that the study is limited to women who are part of the French social security system.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Women ≥ 18 years old
  • Who experienced severe postpartum hemorrhage, defined as blood loss ≥ 1000 mL, following a vaginal delivery in the previous 12 months, in a maternity unit in Finistère
  • Exclusion Criteria:
  • Women who are pregnant at the time of inclusion
  • Women with a known hereditary bleeding disorder (Willebrand's disease, hemophilia carrier, etc.) or acute or chronic Immune thrombocytopenia (ITP) prior to delivery.
  • Women with a known other bleeding pathology prior to delivery
  • Women taking a treatment that interferes with hemostasis, such as aspirin, anticoagulants or non-steroidal anti-inflammatory drugs (biological sampling may be postponed until after the interfering treatment has stopped, in the case of occasional use of the latter).
  • Women on long-term anticoagulant or antiaggregant therapy
  • Women under legal protection,
  • Women not affiliated to the French social security system.

About University Hospital, Brest

The University Hospital of Brest is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. With a strong emphasis on interdisciplinary collaboration, the hospital serves as a hub for cutting-edge clinical trials aimed at improving treatment outcomes across various medical specialties. Leveraging its robust academic affiliations and state-of-the-art facilities, the University Hospital of Brest is committed to fostering scientific discovery and enhancing the quality of life for patients through evidence-based practices and pioneering research initiatives.

Locations

Brest, , France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported